Dirceu Barbano confirmed as head of Anvisa
This article was originally published in RAJ Devices
Dirceu Br�s Aparecido Barbano has been confirmed as director-president of the Brazilian healthcare products regulatory agency Anvisa (Agência Nacional de Vigilância Sanit�ria). He has held this role in a caretaker capacity since January, when his predecessor, clinical analyst Dirceu Raposo de Mello, stepped down after six years at the helm. Mr Barbano joined the Brasilia-based agency as a director in October 2008, with a background specialising in pharmacy.
You may also be interested in...
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.